Application of mannose in the preparation of medicine for treating pulmonary inflammation disease

A technology of mannose and medicine, which is applied in the application field of mannose in the preparation of medicines for treating pulmonary inflammatory diseases, can solve the problems of limited treatment methods, adverse effects, adverse reactions, etc., and achieves low price, strong practicability, and easy The effect of preparation

Inactive Publication Date: 2008-01-02
ZHEJIANG UNIV
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, the treatment methods for the above diseases are limited, mainly based on ventilation support therapy and early application of glucocorticoids on the basis of large doses of antibacterial drugs. Although glucocorticoids can inhibit the accumulation of inflammatory cells and the release of inflammatory mediators, they also It will bring various types of side effects and adverse reactions, such as inhibiting the body's immune response, adversely affecting the body's metabolic function, water-salt balance, etc., and these overlap with the patient's symptoms. Therefore, it is necessary to find effective drugs that inhibit the accumulation and release of inflammatory cells in the acute phase with lower side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mannose in the preparation of medicine for treating pulmonary inflammation disease
  • Application of mannose in the preparation of medicine for treating pulmonary inflammation disease
  • Application of mannose in the preparation of medicine for treating pulmonary inflammation disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 The protective effect of mannose on acute lung injury in mice

[0035] Experimental materials and methods

[0036] 1. Experimental animals

[0037]Clean grade (Grade II) male ICR strain mice (weight 20-22 g) were provided by the Experimental Animal Center of Zhejiang University School of Medicine, certificate number: SYXK (Zhe) 20040052. All operations and experimental procedures complied with the Regulations on the Management of Experimental Animals. Animals had free access to food and water before the experiment.

[0038] 2. Main reagents and instruments

[0039] (1) Lipopolysaccharide (LPS, Esherichia coli O127: B8): Sigma, USA;

[0040] (2) Mannose (D-mannose): American Sigma Company;

[0041] (3) Dexamethasone Sodium Phosphate Injection (dexamethasone, DXM, batch number: 050502): Zhejiang Xianju Pharmaceutical Co., Ltd.;

[0042] (4) Chloral hydrate: domestic analytically pure product;

[0043] (5) Urethane: domestic analytically pure product;

[...

Embodiment 2

[0110] Example 2 The protective effect of mannose on the acute respiratory distress syndrome model in rats

[0111] The medicine prepared from mannose of the present invention, with dosages of 15mg / kg, 45mg / kg, 135 and 405mg / kg, and other monosaccharides such as glucose 135mg / kg, galactose 135mg / kg and fructose 135mg / kg as contrast , administered intravenously to prevent and treat the endotoxin lipopolysaccharide (LPS)-induced acute respiratory distress model in rats. The results showed that mannose could protect LPS-induced arterial partial pressure of oxygen from decreasing, arterial partial pressure of carbon dioxide from increasing, and pulmonary vascular ventilation. Increased permeability, pulmonary edema, accumulation of inflammatory cells in the lung, increased cytokine TNF-α, increased myeloperoxidase (MPO) levels, and decreased superoxide dismutase (SOD) levels. Other monosaccharides such as glucose 135mg / kg, galactose 135mg / kg and fructose 135mg / kg have no obvious e...

Embodiment 3

[0171] Embodiment 3 Mannose prevents and treats severe acute respiratory syndrome (SARS)

[0172] In mid-November 2002, a case of contagious atypical pneumonia of unknown etiology (referred to as SARS) was discovered for the first time in Guangdong Province of my country. The disease spread rapidly in Hong Kong and many countries and regions. Almost all the people who had close contact with the patients were infected, and the infection rate among medical staff was the highest. Therefore, people all over the world, governments and the World Health Organization have paid great attention immediately, and scientific researchers from various countries have also quickly joined in the research on atypical pneumonia (Zhao Xirong, et al. Advances in Clinical and Pathological Research of SARS. China Journal of Hospital Infection 2003, 11(3): 1092-94). Patients with the disease have acute respiratory distress due to severe damage to the respiratory system, and can be transmitted through t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
control rateaaaaaaaaaa
Login to view more

Abstract

The invention provides the application of carubinose in preparing medicine that can treat lung acute inflammation diseases. The molecular formula of carubinose is C6H12O6, the structure is D-carubinose. Said medicine comprises medicine acceptable shaping agent or carrying agent. The produced dosage form mainly comprises liquid dosage form, granule, tablet, gas spraying form, drop or pill. The invention can reduce the lung tissue TNF-alpha level of mice ALT model induced by LPS, release neutral granulocyte wettability in lung tissue, inhibit capillary blood permeability, decrease protein exudation and lung water content, reduce MPO level in BALF supernatant and improve pathologic change for lung tissue inflammation. The invention discloses the functions of anti-inflammation, anti-oxidation and pneumochysis reduction of carubinose.

Description

technical field [0001] The invention belongs to the application of medicine, and relates to the new application of mannose in medicine, in particular to the application of mannose in the preparation of medicines or health care products for treating acute pulmonary inflammatory diseases. Background technique [0002] Mannose (mannose), the name comes from the biblical manna (manna). As one of the aldohexoses, it is not only an isomer with the most well-known glucose, but also has many inseparable relationships. Mannose Molecular Formula C 6 h 12 o 6 , molecular weight 180.16, density 1.539. There are linear and cyclic structures. There are two configurations, D- and L-, and D-mannose is common in nature. [0003] As a sugar, mannose is undoubtedly the primary use of sweeteners, food and beverage additives, followed by medicine, and has a good adjuvant therapeutic effect on patients with diabetes, obesity, constipation and high cholesterol. It is reported that the breed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7004A61K9/08A61K9/10A61K9/12A61K9/16A61K9/20A61P11/00
Inventor 谢强敏邓杨梅徐旋里董新威
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap